Phaseline

Companies › AMO Pharma

AMO Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tideglusib
Glycogen synthase kinase-3 beta inhibitor
GSK3BPhase 2Congenital Myotonic Dystrophy; Arrhythmogenic CardiomyopathyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05004129TideglusibPhase 2Congenital Myotonic DystrophyNeurologyDec 2026
NCT06174220TideglusibPhase 2Arrhythmogenic CardiomyopathyCardiovascularFeb 2027

Targets

GSK3B (1)

Companies with the same targets

Alzamend Neuro Actuate Therapeutics

Companies built like this

Ever Neuro Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.